Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P10720

UPID:
PF4V_HUMAN

ALTERNATIVE NAMES:
C-X-C motif chemokine 4 variant; CXCL4L1; PF4alt; PF4var1

ALTERNATIVE UPACC:
P10720; A1L4S0

BACKGROUND:
The Platelet factor 4 variant, identified through its aliases such as CXCL4L1, PF4alt, and PF4var1, serves as an inhibitor of angiogenesis and modulates endothelial cell chemotaxis in vitro. Its involvement in these critical biological processes underscores its significance in vascular biology and cellular migration.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Platelet factor 4 variant unveils opportunities for novel therapeutic interventions. Given its inhibitory effects on angiogenesis and endothelial cell movement, targeting this protein could lead to innovative treatments for diseases characterized by aberrant angiogenesis and cell migration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.